BALA CYNWYD, Pa., May 22, 2015 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of Synageva
BioPharma Corp. ("Synageva" or "the Company") (Nasdaq -GEVA-News)
for possible breaches of fiduciary duty and other violations of
state law in connection with the sale of the Company to Alexion
Pharmaceuticals, Inc. ("Alexion").
Click here to learn more about the investigation
http://brodsky-smith.com/942-geva-synageva-biopharma-corp.html, or
call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Synageva shareholders will
receive only 0.6581 of an Alexion share and $115.00 in cash for each share of Synageva stock
they own. The transaction values Synageva at only approximately
$225.92 per share. The investigation
concerns whether the Board of Synageva breached their
fiduciary duties to shareholders and whether Alexion is underpaying
for Synageva. The transaction may undervalue Synageva as the
Company has a strong pipeline of protein therapeutic programs
for patients with rare diseases who have unmet medical needs. This
includes Kanuma, for the treatment of Lysosomal Acid Lipase
Deficiency. In addition, an analyst has placed a $230.00 per share price target on Synageva
stock.
If you own shares of Synageva and wish to discuss the legal
ramifications of the investigation, or have any
questions, you may e-mail or call the law office of Brodsky &
Smith, LLC who will, without obligation or cost to you, attempt to
answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith,
LLC, Two Bala Plaza, Suite 510, Bala
Cynwyd, PA 19004, by visiting
http://brodsky-smith.com/942-geva-synageva-biopharma-corp.html, or
calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and class action lawsuits. The attorneys at Brodsky
& Smith have been appointed by numerous courts throughout the
country to serve as lead counsel in class actions and have
successfully recovered millions of dollars for our clients and
shareholders. Attorney advertising. Prior results do not guarantee
a similar outcome.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-brodsky--smith-llc-announces-investigation-of-the-board-of-directors-of-synageva-biopharma-corp--geva-300087896.html
SOURCE Brodsky & Smith, LLC